Clinical Trials
12 trialsNCT02381548 2026-01-30
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03345784 2024-02-20
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01047007 2023-09-21
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01076400 2023-09-18
MK-1775-008
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT04959266 2022-09-16
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
AstraZeneca
Phase 1 Terminated
NCT05008913 2022-09-06
ADME
AstraZeneca
Phase 1 Terminated
NCT04949425 2022-09-02
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Terminated
NCT02688907 2018-09-20
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation
Samsung Medical Center
Phase 2 Terminated
NCT02196168 2017-05-03
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02087241 2017-03-29
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
AstraZeneca
Phase 2 Terminated
NCT02087176 2016-06-14
A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
AstraZeneca
Phase 2 Terminated